As we do not know the threshold willingness to pay value for additional effectiveness associated with CBT, the probability that CBT will be considered cost effective was calculated for a range of threshold values and presented in a cost effectiveness acceptability curve (CEAC).
It is unclear, though, whether the willingness-to-pay for additional effectiveness of health insurance funds corresponds with the IQWiG concept.
These promising findings call for additional effectiveness research to expand the evidence base regarding interventions that positively impact the nutrition environment and increase understanding of the association between the nutrition environment and food purchasing behaviors.
The question in this case would be how much additional costs have to be paid for the additional effectiveness.
The cost effectiveness acceptability curve shows a probability higher than 50%% for the procedure with intraprocedural CEUS to be cost-effective, with a willingness to pay per additional effectiveness unit of €5755.
However, with the WTP values exceeding some €19 000 per QALY gained, the need for additional cost-effectiveness information is low or, saying it with other words, the consequences of that wrong decision would be minimal if RCHOP-R is chosen.
Given our limited knowledge about the effectiveness of most CAM therapies, there is a clear need for additional studies evaluating their effectiveness.
Specifically, this led to a high workload for the involved faculty including substantial personnel management time, on-going coordination with public school sites, management of funding, applying for additional funding, researching the effectiveness of the program, and training and certifying incoming evaluators and working with consultants for external evaluation.
There remains a need for additional investigations of cost effectiveness, clinical applicability, and method standardization.
Both active dose groups showed similar effectiveness for additional efficacy endpoints including creatinine clearance, SCr ratio and serum cystatin C, compared to those of the placebo group.
This highlights the need for additional studies evaluating their effectiveness and suggests that researchers conducting clinical trials of these therapies may not have difficulties recruiting patients.
